Ring Ventures

Ring Therapeutics is a biotechnology company founded by Flagship Pioneering that is pioneering a new class of gene therapy vectors based on the human anellome. The company's proprietary AnelloVector platform leverages anelloviruses, which are commensal, non-pathogenic viruses that naturally reside in humans, to deliver genetic medicines. Unlike traditional viral vectors like AAV, AnelloVectors are designed to be redosable, tissue-specific, and capable of carrying larger genetic payloads without eliciting a significant immune response. Ring is currently advancing a diverse pipeline of programs across multiple therapeutic areas, including ophthalmology, hepatology, and oncology, aiming to overcome the limitations of current gene delivery technologies.